Recent developments in pharmacoeconomic evaluation in Ireland

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 3, 2010, Pages 221-224

  Tilson, Lesley ^a   Barry, Michael ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; GLUCOSAMINE; PRESCRIPTION DRUG;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG MARKETING; ECONOMIC EVALUATION; EDITORIAL; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEMOGLOBINURIA; HUMAN; IRELAND; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHARMACY; POPULATION GROWTH; PRESCRIPTION; PRIMARY MEDICAL CARE; REIMBURSEMENT; COST BENEFIT ANALYSIS; ECONOMICS; PHARMACOECONOMICS; TRENDS;

COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; IRELAND; PRESCRIPTION DRUGS;

EID: 77953723272     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.33     Document Type: Editorial

References (12)

1. Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev. Pharmacoeconomics Outcomes Res. 10(3), 239-245 (2010).
2. Bridges J, Onukwugha E, Mullins D. Healthcare rationing by proxy. Cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics 28, 175-184 (2010).
3. Usher C, Tilson L, Olsen J et al. Cost effectiveness of HPV vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 & 18 using a transmission dynamic model. Vaccine 26, 5654-5661 (2008).
4. Stafinski T, McCabe C, Menon D. Funding the unfundable. Mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 28, 113-142 (2010).
5. Hughes D, Ferner R. New drugs for old: disinvestment and NICE. BMJ 340, C572 (2010).
6. Layte R, Barry M, Bennett K et al. Projecting the impact of demographic change on the demand for and delivery of healthcare in Ireland. Research series number 13 (2009) www.esri.ie/UserFiles/ publications/20091023164031/RS013.pdf (Accessed March 2010)
7. National Centre for Pharmacoeconomics. A review of the cost-effectiveness of sunitinib (Sutent® ) under the High Tech Drug Scheme in Ireland. October 2006 www.ncpe.ie/u-docs/doc-129.pdf (Accessed April 2010)
8. National Centre for Pharmacoeconomics. Economic evaluation of agomelatine (Valdoxan® ) for the treatment of major depressive disorder. September 2009 www.ncpe.ie/u-docs/doc-176.pdf (Accessed April 2010)
9. Health Information and Quality Authority. Health technology assessment of the role of human papillomavirus vaccines in reducing the risk of cervical cancer in Ireland (2008) www.hiqa.ie (Accessed March 2010)
10. National Centre for Pharmacoeconomics. An economic evaluation of eculizumab (Soliris® ) for the treatment of paroxysmal noctural haemoglobinuria (PNH) in the Irish healthcare setting. March 2010 www.ncpe.ie/u-docs/doc-188.pdf (Accessed March 2010)
11. Department of Health and Children. Economies in drug usage in the Irish healthcare setting (2009) www.dohc.ie (Accessed June 2009)
12. National Centre for Pharmacoeconomics. Economic evalution of glucosamine sulfate (DONA® ) for the treatment of oestoarthritis in the Irish Healthcare setting. June 2009 www.ncpe.ie/u-docs/doc-171.pdf (Accessed March 2010)